To determine pathologic features associated with recurrence and survival in patients with lymph node-negative gastric adenocarcinoma. Study Design: Multi-institutional retrospective analysis. Background: Lymph node status is among the most important predictors of recurrence after gastrectomy for gastric adenocarcinoma. Pathologic features predictive of recurrence in patients with node-negative disease are less well established. Methods: Patients who underwent curative resection for gastric adenocarcinoma between 2000 and 2012 from 7 institutions of the US Gastric Cancer Collaborative were analyzed, excluding 30-day mortalities and stage IV disease. Competing risks regression and multivariate Cox regression were used to determine pathologic features associated with time to recurrence and overall survival. Differences in cumulative incidence of recurrence were assessed using the Gray method (for univariate nonparametric analyses) and the Fine and Gray method (for multivariate analyses) and shown as subhazard ratios (SHRs) and adjusted subhazard ratios (aSHRs), respectively. Results: Of 805 patients who met inclusion criteria, 317 (39%) had nodenegative disease, of which 54 (17%) recurred. By 2 and 5 years, 66% and 88% of patients, respectively, experienced recurrence. On multivariate competing risks regression, only T-stage 3 or higher was associated with shorter time to recurrence [aSHR ¼ 2.7; 95% confidence interval (CI), 1.5-5.2]. Multivariate Cox regression showed T-stage 3 or higher [hazard ratio (HR) ¼ 1.8; 95% CI, 1.2-2.8], lymphovascular invasion (HR ¼ 2.2; 95% CI, 1.4-3.4), and signet ring histology (HR ¼ 2.1; 95% CI, 1.2-3.6) to be associated with decreased overall survival. Conclusions: Despite absence of lymph node involvement, patients with Tstage 3 or higher have a significantly shorter time to recurrence. These patients may benefit from more aggressive adjuvant therapy and postoperative surveillance regimens.
D espite declining global incidence, gastric adenocarcinoma (GAC) remains the fourth leading cause of worldwide cancer-related mortality. 1 The cornerstone of curative therapy for gastric cancer remains surgical resection with negative margins and an adequate lymphadenectomy, 2 but adjuvant chemotherapy and chemoradiation have shown survival benefits when added to resection. 3, 4 It is well established that lymph node status is among the most important prognostic factors for disease recurrence and survival in resected gastric cancer. [5] [6] [7] Although lymph node-negative patients demonstrate substantially better outcomes than those with lymph node metastases at the time of resection, a subset of these patients experience recurrence and disease-specific death. Identifying factors associated with recurrence and decreased survival in patients with node-negative disease can improve patient selection for adjuvant therapy and surveillance.
Several reports have examined prognostic factors in nodenegative GAC. 5, [8] [9] [10] [11] [12] [13] [14] [15] However, these studies generally represent single-center experiences, the majority of which come from Eastern centers. Only 4 available studies are from Western populations. 5, 11, 12, 15 Here, we use data from the 7 institutions that make up the US Gastric Cancer Collaborative to identify prognostic factors for recurrence in lymph node-negative gastric cancer after curative resection in a large, modern, multicenter North American cohort. manager (M.H.S.). Demographic, preoperative, intraoperative, and pathologic data were collected from the medical record. Preoperative disease assessment was based on a combination of cross-sectional imaging and endoscopic ultrasonography; locally advanced disease was defined as bulky tumor or lymph node involvement seen on either modality. Pathology staging was assigned per American Joint Committee on Cancer, Seventh Edition, 16 where depth of invasion is defined by T1 tumors invading the lamina propria, muscularis mucosae, or submucosa; T2 tumors invading the muscularis propria; T3 tumors penetrating subserosal connective tissue without invasion of visceral peritoneum or adjacent structures; and T4 tumors invading serosa or adjacent structures. Data regarding neoadjuvant and adjuvant therapies, postoperative outcomes, recurrence, and overall survival (OS) were collected, and survival data were verified with the Social Security Death Index. Institutional review board approval was obtained at each participating institution.
Only patients undergoing resections with curative intent were included; patients undergoing palliative resection, patients with zero nodes retrieved, those with known metastatic disease (American Joint Committee on Cancer stage IV), and 30-day perioperative mortalities were excluded from analysis. We included patients with a range of lymph nodes retrieved from 1 to 54, to investigate outcomes in a clinically realistic cohort of patients termed ''node negative,'' while acknowledging the potential for understaging. The primary objective was to evaluate which factors significantly impact time to recurrence in patients with node-negative GAC after curative resection. Secondary objectives included evaluating factors associated with OS and impact of recurrence pattern on survival. Recurrence patterns were classified as local (anastomotic or gastric remnant), regional (regional lymph nodes), or distant (peritoneal, hepatic, pulmonary, or other sites of metastatic disease). Patients who experienced recurrence in more than 1 pattern (ie, local and distant) were evaluated in the more distant or aggressive subgroup (ie, a patient experiencing recurrence locally and distantly was evaluated with the distant metastasis group).
Statistical Analysis
Perioperative and clinicopathologic factors were compared using x 2 analysis for categorical variables and the Student t test or analysis of variance for continuous variables as indicated. Time to recurrence was analyzed using competing risks methodology, which is the appropriate technique when a large proportion of patients experience a competing event (death) before experiencing the event of interest (recurrence). The Kaplan-Meier method estimates the probability of disease recurrence with the assumption that no deaths occur, which is unrealistic in this population of patients with nodenegative disease and may significantly overestimate the incidence of the event of interest. 17 Instead, competing risks methodology estimates the risk of disease recurrence by accounting for death as a competing event. 18, 19 Patients were followed from the time of surgery and censored if they were alive without documented disease recurrence at the time of last follow-up. We investigated the effect of pathologic features on the cumulative incidence of recurrence over time. Differences in the cumulative incidence of recurrence were assessed using the Gray method (for univariate nonparametric analyses) and the Fine and Gray method (for multivariate analyses), shown as subhazard ratios (SHRs) and adjusted subhazard ratios (aSHRs), respectively. 20 These methods consider the effect of predictors on the subhazard function (cumulative incidence function) accounting for the presence of competing risks. 18 Kaplan-Meier survival plots were calculated for OS, and multivariate Cox regression was performed to assess the effect of various pathologic variables on OS. Statistical significance was predefined at P < 0.05. All statistical analyses were done in STATA v.13.1 (StataCorp LP, College Station, TX).
RESULTS
Of 805 patients who met inclusion criteria, 317 patients (39%) had lymph node-negative disease. In this cohort, 54 patients (17%) experienced disease recurrence after a median follow-up time of 68 months. Patients with node-negative disease had a mean age of 66 (SD ¼ 12) years and 44% were female. Clinicopathologic characteristics shown by recurrence status are summarized in Table 1 . The 2 groups did not differ with respect to sex, age, race, comorbidities, or American Society of Anesthesiologists class. Patients who experienced recurrence were more likely to have a preoperative clinical assessment of locally advanced disease (defined as bulky tumor or lymph node involvement seen on preoperative imaging or endoscopic ultrasonography) than patients who did not experience recurrence (54% vs 34%; P < 0.001), correlating with more advanced disease. Three patients received a preoperative assessment of metastatic disease, of which all received neoadjuvant chemotherapy and subsequently underwent curative resection with no pathologic evidence of metastases; postoperatively, 1 patient was pathologically staged as stage I and 2 patients were pathologically staged as stage II. A significantly higher proportion of patients who experienced recurrence underwent neoadjuvant chemotherapy (43% vs 19%; P < 0.001). In total, 27 patients underwent a staging laparoscopy as a stand-alone procedure before resection or neoadjuvant therapy. Of these, 2 patients had positive cytologic results and subsequently received neoadjuvant chemotherapy and underwent resection with curative intent. In addition, 110 patients underwent a diagnostic laparoscopy at the time of curative resection. Of these, cytologic specimens were sent in 18 patients, all of which gave negative results.
With respect to operative characteristics, no significant differences existed in the type of operation, extent of nodal dissection, mean or median number of total nodes examined, or the likelihood of having had more than 15 nodes examined between the 2 groups. In general, the majority of patients received either a subtotal or total gastrectomy (44% and 37%, respectively) and 56% of patients underwent at least a D2 lymphadenectomy. The mean number of total nodes examined was 16.9 (SD ¼ 11); the median number of total nodes examined was 16 (interquartile range ¼ 9-22). We also examined the total nodes retrieved by T-stage to determine whether risk of nodal understaging increased with T-stage. The median number of nodes examined was 16 for T1 tumors, 14 for T2 tumors, 15 for T3 tumors, and 18 for T4 tumors; these differences were not statistically significant (P ¼ 0.79). The rates of perioperative blood transfusion, postoperative complications, and readmissions did not differ significantly by recurrence status. The rate of adjuvant therapy was significantly higher among patients who experienced recurrence (54% vs 22%; P < 0.001).
The majority of patients presented with tumors of the gastric antrum (35%) or body (38%); this did not differ between the 2 groups. However, univariate analysis did reveal that patients who experienced recurrence tended to have larger tumors (5.0 cm vs 3.1 cm; P ¼ 0.001), higher T-stage, and higher rates of poor histologic grade (65% vs 45%; P ¼ 0.001), signet ring histology (48% vs 30%; P ¼ 0.01), lymphovascular invasion (LVI) (26% vs 13%; P ¼ 0.02), and perineural invasion (PNI) (30% vs 10%; P < 0.001). Recurrence was associated with more aggressive disease on pathology.
The median follow-up time for all patients with node-negative GAC was 68 months after resection. Of the 54 patients who experienced recurrence, 36 (66%) had experienced recurrence by 2 years and 48 (88%) had experienced recurrence by 5 years. Table 2 shows (Table 3 ). In contrast to the time to recurrence analysis, having had more than 15 nodes examined was associated with improved OS (HR ¼ 0.6; 95% CI, 0.4-0.9; P ¼ 0.01).
Of the 54 patients who experienced recurrence, 18 (33%) had local, 16 (29%) had regional, and 38 (70%) had distant recurrence. This distribution did not differ significantly from patients who experienced recurrence after resection for lymph node-positive disease (P ¼ 0.31). Thirty-two patients (59%) experienced recurrence in 1 location, whereas 22 patients (41%) experienced recurrence in more than 1 location. There were no significant differences in demographic, clinical, operative, or pathologic features when stratified by recurrence pattern. Although there was a trend toward larger mean tumor sizes (3.2, 5.0, and 5.7 cm for local, regional, and distant recurrence, respectively), higher rates of PNI, LVI, and diffuse Lauren-type histology in patients who experienced recurrence distantly, these differences did not reach statistical significance. In addition, the OS function did not show significant separation when stratified by recurrence pattern (P ¼ 0.21). The distribution of recurrence patterns also did not differ in patients who were significantly understaged ( 5 nodes examined) (P ¼ 0.35).
Included in this analysis were 74 patients who received neoadjuvant therapy. The treatment regimens and the number of cycles received varied. Possible regimens included epirubicin, cisplatin, and 5-fluorouracil; epirubicin, oxaliplatin, and capecitabine; and FOL-FOX, among others. Among patients who received neoadjuvant therapy, the recurrence rates were higher than those in the general cohort (31% vs 17%). Forty-nine percent of patients who received neoadjuvant therapy also received adjuvant therapy, although the rate of adjuvant therapy in this group did not vary by recurrence status (P ¼ 0.86). Among patients who underwent neoadjuvant therapy, we did not observe a difference in distribution of recurrence types (P ¼ 0.92).
DISCUSSION
It is well established that the presence of nodal metastases is among the strongest prognostic indicators in GAC. 5 Despite this, a subset of patients with lymph node-negative disease will go on to experience recurrence and disease-specific death. These patients may benefit from more aggressive adjuvant therapy, which has been shown to improve survival when compared with gastrectomy alone. 3, 4 Identifying prognostic indicators for recurrence after curative resection has been the focus of several previous studies in nodenegative GAC. 9 -12,15,21-23 However, neither the methods nor results of these prior studies have been consistent. Furthermore, the majority of these reports represent the Eastern experience with GAC. To the best of our knowledge, the present analysis is the largest series of lymph node-negative GAC patients in a multi-institutional Western cohort. Our median follow-up time was substantial at nearly 6 years. In this cohort, 41% of patients undergoing curative resection for GAC had node-negative disease, and 17% of these patients developed recurrence. Both of these figures correspond well to previously published data. 8, 11, 22 We evaluated several endpoints of interest, including time to recurrence and OS. Our data showed that greater depth of tumor invasion (as indicated by T-stage) was independently significant in predicting time to recurrence whereas OS was negatively impacted by higher tumor stage, LVI, and signet ring histology.
The most consistent risk factor for both time to recurrence and OS was depth of tumor invasion. Among other studies of lymph node-negative gastric cancer, depth of tumor invasion and specifically serosal invasion have been the most consistently reported risk factors for both recurrence and survival. 8, 11, 12, 15, 23, 24 Previous studies of lymph node-negative GAC have excluded T1 tumors 15 or used only T4 status to dichotomize the study population. 2, 11, 21 However, in our data set, the majority of patients who experienced recurrence had T3 tumors, with T4 tumors being a close second (Table 1 ). By dichotomizing our study population into patients with T1/T2 tumors and T3/T4 tumors, we showed a significant separation in every endpoint, suggesting that patients with T3 tumors should also be strongly considered for adjuvant therapy. Several Eastern series have reported tumor size as a significant prognostic factor in node-negative gastric cancer. 7, 14, 21, 25 Unlike other solid tumors such as in breast and lung cancer, tumor size is not currently included in the classification of GAC. However, Saito and colleagues 14 recently reported that patients with advanced nodenegative gastric cancer with an average tumor size of 6 cm, tumor size 7 cm or larger was associated with significantly decreased 5-year OS. This group has also reported that tumor size closely correlates with prognosis in all GAC patients. 23 Interestingly, in the 4 Western series of node-negative gastric cancer in the literature, tumor size is mentioned only by Baiocchi et al 15 and Kooby et al, 11 and neither of these studies found tumor size to significantly increase the hazard over time for survival or recurrence. In our own series, tumor size became slightly nonsignificant on multivariate analyses of time to recurrence (P ¼ 0.07) and lost any significance on multivariate Cox regression of survival (P ¼ 0.76).
Our analysis found neural invasion, vascular invasion, poor histologic grade, diffuse Lauren-type histology, and signet ring histology to be significant risk factors for decreased time to recurrence on univariate competing risks regression but to lose their significance when controlling for T-stage. On the basis of existing reports in the literature and our present study, the value of these prognostic factors is not clear. Previously, Hyung et al 26 reported that having LVI was a negative prognostic factor. Saito and colleagues 14 reported that poor histologic grade was a negative risk factor, whereas Gronnier et al 27 showed that signet ring histology may actually correlate with improved prognosis in early gastric cancer. Meanwhile, Baiocchi et al 15 reported in the only other multi-institutional Western series of node-negative GAC that LVI, neural invasion, and tumor grade were all insignificant prognosticators of recurrence. Although these features may indicate more aggressive disease, their effect seems to be outweighed by that of T-stage and tumor size. In a series from Memorial Sloan Kettering Cancer Center, D'Angelica and colleagues 28 showed that recurrence after complete resection for GAC is usually early and fatal, with nearly 80% of patients experiencing recurrence within 2 years. Although patients with lymph node-negative disease have a significantly lower rate of recurrence, our data showed that patients who do experience recurrence do so rapidly, the majority within 2 years. Predictors of recurrence pattern and the implications for survival have previously been examined only in Eastern series of lymph node-negative GAC. [8] [9] [10] Chou and colleagues 8 demonstrated that T4 status was a predictor for locoregional recurrence and peritoneal seeding whereas larger tumor size and the presence of PNI predicted hematogenous spread. They also found that survival was better in patients who only had locoregional recurrence. 8 In the current analysis, we observed a corresponding trend toward larger tumor size, higher rates of PNI and LVI, and diffuse Lauren-type histology in patients who experienced recurrence distantly (hematogenously), although these trends did not reach statistical significance. It is likely that this analysis was limited by sample size, and these associations should be considered in future series of Western patients. Because of database limitations, we were also unable to analyze recurrence pattern of local, regional, or distant recurrence as independent time-varying variables, another analysis that would be useful to perform in future, larger studies of gastric cancer. This is the first report of node-negative GAC in which a substantial proportion of patients underwent preoperative chemotherapy. The 2 most recent Western series available report patient data from 1985 to 2001, 11 and 1992 to 2002, 15 both predating the MAGIC trial establishing the survival benefit associated with perioperative chemotherapy. Our own data set spans from 2000 to 2012, during which a variety of treatment regimens were used. The recurrence rate was higher among patients who received neoadjuvant therapy than those who did not, which correlates with the assessment of more locally advanced disease preoperatively. However, only half of the patients who received neoadjuvant therapy also received adjuvant therapy, and in this cohort, the receipt of adjuvant therapy did not differ between patients who experienced recurrence and patients who did not. This highlights room for improvement in completing postoperative adjuvant therapy in this patient population. Given the retrospective nature of this analysis, it is difficult to give exact indications used for adjuvant therapy. In general, the indications for adjuvant chemotherapy in gastric cancer include completion of preoperative therapy (planned) or adjuvant chemoradiation along the MacDonald protocol. However, in lymph node -negative patients, clear indications based on level I data are lacking.
The question of adequate lymph node dissection in patients deemed lymph node-negative has been extensively discussed. 5, 8, 11, 22, 29, 30 In general, it is believed that more extended lymphadenectomy (D2 or greater) conveys a survival benefit, especially in patients with higher T-stage disease. 5, 29, 30 Jiao et al 22 have also shown that a greater number of total examined lymph nodes may confer a survival benefit in patients with node-negative cancer. Large population studies of gastric cancer from various institutions and countries have demonstrated a significant association between the number of examined lymph nodes and OS, leading the latest TNM staging system to recommend that at least 15 lymph nodes should be examined for the accurate N staging. 31, 32 In our study population, 56% of patients received at least a D2 lymphadenectomy and 51% had more than 15 total nodes examined. There was a slight trend toward higher number of total nodes retrieved from 2000 to 2012. However, we did not find the rates of D2 dissection or having more than 15 nodes examined to differ significantly by recurrence status, although having more than 15 total nodes examined was protective on multivariate analysis of OS. Although a significant proportion of our patients were technically understaged, it is interesting to find that by including them in our analysis, the degree of lymphadenectomy and total lymph nodes examined were not associated with recurrence. Even in the subset of T3 or higher tumors, the rate of having a D2 dissection or having more than 15 nodes examined did not differ significantly by recurrence status, nor did the median number of total nodes examined. Although the possibility of understaging and stage migration is important and nontrivial, we decided to analyze the pathologic features associated with recurrence in this group of potentially heterogeneous ''nodenegative'' patients regardless of total nodes examined. A recent multicenter report of colorectal cancer treatment in the United Kingdom found that more than half of patients undergoing resection did not meet the national guidelines of having 12 or more nodes examined 33 and understaging in colorectal cancer is an indication to receive adjuvant therapy. 34 In addition, the number of total nodes examined depends heavily on pathology techniques, which account for some of the differences between Eastern and Western reports of gastric cancer. At present, there are no firm guidelines for adjuvant therapy in patients with understaged GAC. Reoperation for adequate staging is unrealistic, and clinical decision making for adjuvant therapy may be best derived from data of a representative cohort, as shown in the current report. Therefore, our analysis helps provide some guidance for higher risk node-negative patients based on other adverse pathologic features.
This study represents a retrospective analysis from 7 academic institutions in the United States. Although there are clear strengths to our analysis, there are also several limitations that should be acknowledged. As a retrospective, observational study, we are limited in drawing definitive conclusions of causality. Furthermore, despite the robust, multi-institutional nature of the US Gastric Cancer Collaborative database, node-negative gastric cancer remains a rare entity. In comparing subgroups by recurrence pattern, our sample size may be insufficiently powered to detect true differences that exist. In addition, this database represents only university-based experience and does not include gastric cancer cases treated in the community, which represents a significant portion of cases treated in the United States.
Despite these limitations, this analysis is significant as the largest study to quantify risk factors for recurrence in patients with lymph node-negative gastric cancer in a multi-institutional Western cohort and the only one to do so using competing risks methodology. We modeled the hazard of recurrence over time with the occurrence of death as a competing event that would hinder the outcome of interest. All prior studies of node-negative gastric cancer analyzed recurrence using the Kaplan-Meier method, which in the setting of competing risks may overestimate the occurrence of the main outcome by as much as 30% compared with the cumulative incidence method. 17 Therefore, we believe that the present methodology more accurately models the event of recurrence.
CONCLUSIONS
We found that T-stage 3 or higher is associated with decreased time to recurrence in patients with node-negative gastric cancer whereas higher T-stage, LVI, and signet ring histology were associated with decreased survival. As such, these high-risk patients may benefit from adjuvant therapy and closer surveillance. Future work may focus on identifying new pathologic or molecular features that can improve accuracy of staging in patients with lymph nodenegative gastric cancer.
